8-K: Current report filing
Published on July 27, 2021
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C.20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): July 27,
2021
KNOW LABS, INC.
(Exact
name of registrant as specified in its charter)
Nevada
|
000-30262
|
90-0273142
|
(State
of other jurisdiction
|
(Commission
|
(IRS
Employer
|
of
incorporation)
|
File
Number)
|
Identification
No.)
|
500 Union Street, Suite 810
Seattle, Washington 98101
(Address
of principal executive office)
(206) 903-1351
(Registrant’s
telephone number, including area code)
(Former
name, former address and former fiscal year, if changed since last
report)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
☐ Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a -12)
☐ Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
☐ Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
Securities
registered pursuant to Section 12(b) of the Act: None
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (§240.12b-2 of this chapter).
Emerging
growth company. ☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act.
☐
Item 8.01 Other
Events.
On July 27, 2021, Know Labs, Inc. (the “Company”), an
emerging leader in non-invasive
medical diagnostics, announced that it had been granted the
following three patents:
–
U.S.
Patent No. 11,063,373: Non-invasive analyte sensor and system with
decoupled transmit and receive antennas
–
U.S.
Patent No. 11,031,970: Non-invasive analyte sensor and system with
decoupled and inefficient transmit and receive
antennas
–
U.S.
Patent No. 11,058,317:
Non-invasive detection of an analyte using decoupled and
inefficient transmit and receive antennas
The
patents were issued by the United
States Patent and Trademark Office. Each of the newly issued
patents relates to the unique configuration of the antennas used in
Know Labs’ Bio-RFID sensors. This unique arrangement enhances
Bio-RFID’s performance and improves its detection
capabilities in identifying and measuring a variety of analytes
non-invasively. The patents support the Company’s
medical diagnostic focus while also signaling potential for
additional non-medical applications. These new patents expand Know Labs’
intellectual property portfolio in radio frequency and microwave
spectroscopy, further improving its technological position as it
readies to launch non-invasive diagnostic
devices.
A copy of the press release is attached hereto as Exhibit 99.1 and
is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
Exhibit No.
|
|
Description
|
|
|
|
|
Press
release dated July 27, 2021. Filed herewith.
|
-2-
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Registrant:
KNOW LABS, INC.
By: /s/
Ronald P. Erickson
Ronald
P. Erickson
Chairman of the
Board
July
27, 2021
-3-